The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2024 | Developments in the treatment of multiple and smoldering myeloma from ASH 2024
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, comments on the revolution in multiple myeloma treatment, highlighting the promising results of novel therapies for early-stage myeloma and high-risk smoldering myeloma. He emphasizes the importance of achieving measurable residual disease (MRD) negativity for long-term control and speaks about CAR-T therapies, which show promise in the relapsed/refractory setting. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
